SECTION 1: CLINICAL AND PREVENTIVE CARDIOLOGY

1. Development of Cardiology in India: Where are We Today? ................................................................. 3
   S Padmavati
   - Cardiac situation  3
   - Medical manpower  3
   - Cardiac manpower  4
   - Cardiothoracic surgery  4
   - Training programs  4
   - Centers for tertiary care  4
   - Comparison with industrialized countries  4
   - Quality of cardiac care  4
   - Research  4
   - Prevention  5

   Parneesh Arora, Upendra Kaul
   - New antiplatelet drugs  6
   - Antithrombotic agents  6

3. Impact of Kidney Disease on the Outcome and Management of Acute Coronary Syndrome ................................................................. 11
   Binoy John
   - Impact of acute kidney injury on acute coronary syndrome  11
   - Impact of chronic kidney disease on acute coronary syndrome  12
   - Antiplatelet agents in chronic kidney disease patients with acute coronary syndrome  15
   - Anti-ischemic agents and statins in chronic kidney disease patients with acute coronary syndrome  15
   - Antithrombotic therapy in chronic kidney disease patients with acute coronary syndrome  18

   G Vijayaraghavan, Sadath Pareed
   - Mechanism  22
   - Genetic variability on platelet function test  24
   - Predicting adverse cardiovascular events  24
   - Treating aspirin and clopidogrel resistance  24
   - Future direction and clinical consideration  25

5. Gold or Old Standard: New Insights on Aspirin in Cardiovascular Diseases (CVD) Prevention ................................................................. 27
   Mukesh Kumar Sharma, SK Kaushik
   - Aspirin in primary prevention of CVD  27
   - Aspirin for primary prevention in specific populations  28
   - Optimal dose and preparation of aspirin  29
Summary of recommendations on prophylactic aspirin use (various organizations) ........................................... 29
Guidelines and recommendations: patients with diabetes .................................................................................. 29

6. Changing Landscape of Oral Anticoagulants: The Last Pieces of the Puzzle ........................................... 31
   Anjan Lal Dutta, Ratnesh N Rokade, Rajarshi Dutta
   Dabigatran .................................................................................................................................................. 31
   Rivaroxaban ............................................................................................................................................... 31
   Apixaban ..................................................................................................................................................... 32
   Edoxaban ................................................................................................................................................... 32
   Concomitant use of NOAC and digoxin ....................................................................................................... 32
   Transition to oral vitamin K antagonists from novel oral anticoagulants ...................................................... 32
   Bleeding in patients recieving novel oral anticoagulants ............................................................................ 32
   Acute coronary events and novel oral anticoagulants .................................................................................. 33
   Renal impairment and novel oral anticoagulants .......................................................................................... 34
   Warfarin versus novel oral anticoagulants: a revisit ................................................................................... 34

   AK Pancholia
   Nonpharmacological therapies .................................................................................................................. 36
   Pharmacotherapies ...................................................................................................................................... 39
   Cell therapy ................................................................................................................................................. 41
   Others ........................................................................................................................................................ 43

   PC Manoria, Pankaj Manoria, Piyush Manoria, SK Parashar
   Diabetes: a cardiovascular disease .............................................................................................................. 46
   Diabetes, incretin defect and glitkins ........................................................................................................... 46
   Glitkins: a cardiologist’s viewpoint ............................................................................................................ 47

9. Statins as Primary Preventive Strategy ........................................................................................................... 50
   Rajan Joseph Manjuran
   Cardiovascular disease: the global burden .................................................................................................. 50
   Cardiovascular disease in India ................................................................................................................ 50
   Current use of statins in primary prevention of CVD ................................................................................ 50

10. Management of Atherogenic Dyslipidemia Triad: Indian Perspective ......................................................... 54
    Sivakadaksham, Sameer Dani, Prashant Advani
    Common link between dyslipidemia/diabetes and CVD: insulin resistance syndrome ............................ 54
    Pathogenesis of atherogenic dyslipidemia triad of insulin resistance and type 2 diabetes .................... 54
    Lipid triad accelerates atherosclerosis via multiple mechanisms .............................................................. 55
    Management of dyslipidemic triad ............................................................................................................. 56

11. Lipid Management Beyond Statins Targeting HDL and TG: Challenges 2014 ............................................. 59
    Saumitra Ray
    Etiopathogenesis of diabetic dyslipidemia ................................................................................................. 59
    Concept of therapy of atherogenic dyslipidemia ....................................................................................... 60

12. Management of Hypertriglyceridemia and Cardiovascular Risk Reduction ................................................. 66
    RR Mantri, C Raghu, Sanjeev K Sharma
    Prevalence of hypertriglyceridemia with Indian perspective .................................................................... 66
    Hypertriglyceridemia and cardiovascular risk .......................................................................................... 67
Management of hypertriglyceridemia 68
Pharmacotherapy for hypertriglyceridemia 68
Pharmacokinetics 69
Clinical studies 69

13. Beta-blockers and Coronary Artery Disease: Status 2014 ................................................................. 72
PP Mohanan
- Anti-ischemic effects of beta-blockers 72
- Beta-blockers in acute coronary syndrome: ST-segment elevation in myocardial infarction 72
- Secondary prevention 73
- Stable coronary artery disease 74
- Reduction of atherothrombosis for continued health registry and questions about the cardioprotective efficacy of beta-blockers? 75

14. Statin Guidelines: Controversies to Consensus (What to Follow in 2014?) ........................................... 77
Santanu Guha, Siddhartha Mani, Suchit Majumdar
- Scope of the guidelines 77
- Whom to treat? 77
- What to treat? 78
- How to treat? 78

15. ARBs and CVD Protection: New Dimension 2014 .............................................................................. 81
Vijay K Trehan, Ankit Bansal
- Hypertension 82
- Heart failure 82
- Myocardial infarction 82
- Renal function 82
- Diabetes 82
- Stroke 83
- Left ventricular hypertrophy 83
- Atrial fibrillation 83

16. Amiodarone and Cardiovascular Disease Protection: Clinical Implications 2014 .............................. 85
Mrinal Kanti Das
- Molecular structure 85
- Electrophysiological properties 86
- Dosing 86
- Metabolism 86
- Indications 87
- Evidences with some key trials with the drug 88
- Adverse effects of amiodarone 88

17. Gaps and Challenges in Antiplatelet Therapy: Indian Perspective ....................................................... 90
Balaji Pakshirajan, Ajit Mullasari
- Antiplatelet agents 90
- Antiplatelet drugs under development 93
- Guidelines for antiplatelet therapy 93
- Current choice of antiplatelet therapy: Indian perspective 93

18. Triple Antiplatelet Therapy in Acute Coronary Syndrome in 2014 ......................................................... 97
Rajeev Lochan
- Antiplatelet agents 97
19. Drug–Drug Interactions in Cardiology ................................................................. 103
   S Nagendra Boopathy, Ambuj Roy
   Incidence and prevalence  103
   Classification 103
   Drug–drug interactions in patients with heart failure  103
   Coronary artery disease  105
   Arrhythmia 106
   Hypertension 107
   Prosthetic heart valve 107
   Herbal interactions 107
   Drug interactions identification software 107

20. Pharmacoinvasive Strategy in the Treatment of STEMI .................................... 109
    Tiny Nair
    Evolution of stemi management 109
    Mechanical reperfusion versus thrombolysis 109
    Problems of delay in therapy  110
    Early thrombolysis with fibrin-specific agents 110
    Problems with thrombolytic therapy 110
    Combined approach of reperfusion: can we avoid the delay? 110
    Pharmacoinvasive strategy 111
    The future: time delay between thrombolysis and PCI in pharmacoinvasive treatment 112

    Satyendra Tewari, Ashok Kumar
    Care of post-PTCA patient 114
    Care of post-CABG patient 117

    Satyajeet N Suryawanshi, Shirish (MS) Hiremath
    Improved level of care for ST-segment elevation myocardial infarction 119
    Recent advances in medical therapy for acute coronary syndrome—antiplatelet therapy 120

SECTION 2: CORONARY ARTERY DISEASE

23. Genetics and Coronary Artery Disease—Challenges ......................................... 127
    Soumitra Kumar, Soumen Bhat
    Genetics and CAD 127
    Genome wide association studies and CAD 127
    Utility in clinical practice 129
    What is the role of gene therapy? 129

24. Coronary Artery Disease: Risk Factor Stratification .......................................... 131
    Geevar Zachariah
    Who should go for coronary artery disease risk stratification? 131
    Who need not to go for risk stratification? 131
    Risk stratification models 131
    Limitations of current risk stratification models 134

25. Vitamin D and Cardiovascular Disease ............................................................. 136
    Sunil Modi, Arif Wahab
    Vitamin D: physiology and basics 136
    Risk factors 137
Association of vitamin D and cardiovascular disease 137
Treatment of vitamin D deficiency 139
Vitamin D and cardiovascular disease: does it really matter so much? 139

26. Tobacco and Heart .................................................................................................................. 141
   Ishita Rawal, Ajay S Vamadevan, Dorairaj Prabhakaran
   Prevalence and impact of tobacco use 141
   Pathophysiology: tobacco and heart disease 141
   Risk of heart disease 142
   Benefits of tobacco cessation 144
   Tobacco cessation interventions 145
   Tobacco regulation 145
   Challenges to tobacco control 146

27. Stress and Heart ...................................................................................................................... 150
   Satish Kumar Gupta
   Historical perspectives 150
   What is stress? 151
   Model of stress response 151
   Acute versus chronic stress 151
   Brain–heart connection 152
   Natural history of stress-induced heart disease 152
   Pathophysiological mechanism of stress and CAD 154
   Stress cardiomyopathy 155
   Spirituality, stress, and heart health 156
   Therapeutic implications 157
   Our experience 157
   Future research and perspectives 158

28. Role of Psychosocial Factors and Relaxation Techniques in the Etiology and Prevention of Cardiovascular Diseases .................................................................................. 160
   Priya Chockalingam, Anand Chockalingam, V Chockalingam
   Psychosocial factors and cardiovascular diseases 160
   Ideal cardiovascular health and behavioral cardiology 161
   Positive psychological well-being and relaxation techniques 161

29. Trans Fat and Cardiovascular Disease .................................................................................. 165
   SKD Bhardwaj
   What are trans fats? 165
   Source of trans fats 165
   How do trans fats affect you? 165
   Result of study on trans fats 165
   Trans fats and coronary heart disease 165
   Systemic inflammation 166
   Potential molecule mechanism 166
   How to reduce artificial trans fat? 166
   American Heart Association/American College of Cardiology recommendation 166
   How much trans fat can I eat a day? 166

30. Homocysteine and Coronary Artery Disease ....................................................................... 168
   GS Sainani
   Biochemistry of homocysteine 168
   Estimation of total homocysteine levels 169
Relation between hyperhomocysteinemia and endothelial cell dysfunction 169
Treatment of hyperhomocysteinemia 170

31. State-of-the-art Review on Metabolic Syndrome, Diabetes, and Cardiovascular Disease ............................................................................................................................................... 173
Prakash Deedwania
Background 173
Prevalence 173
Pathophysiology of cardiometabolic syndrome 174
Clinical implications 174
Therapy 174
Progression from metabolic syndrome to diabetes and cardiovascular disease 177
Management of individual risk factors 178

32. Vulnerable Plaque in a Vulnerable Patient: How to Manage? ........................................................................... 184
Varun Gupta, Sandeep Singh
Mechanisms converting a stable plaque to a VP 184
Identifying the VP 185
Identifying the vulnerable patient 185
Treatment strategies 185

33. Microvascular CAD: Management Issues 2014 ............................................................................................... 189
Manish Aggarwal
History 189
Classification 189
Risk factors for coronary microvascular dysfunction 189
Pathophysiology 190
Management 190

34. Hormone Replacement Therapy and Heart ........................................................................................................... 193
Vinod Sharma, Sibaji Phaujdar, Ruchi Sharma
Age-related effects of hormone replacement therapy 194

35. Lifestyle and Coronary Artery Disease .................................................................................................................. 196
SC Manchanda, Kushal Madan
What is lifestyle? 196
Role of yoga 198
Evidence for lifestyle modifications 198

36. Using Health Behavior Change Theory to Guide Health Promotion to Prevent Noncommunicable Diseases in India ................................................................................................................. 201
Mahati Chittem, Sriramya Vemulakonda, Ramesh B Byrapaneni
Health behavior theories 201
Using health behavior theory to guide health promotion in preventing noncommunicable diseases 203

SECTION 3: HEART AND NUTRITION

37. Nutrition and Heart .............................................................................................................................................. 207
Adarsh Kumar, Harharpreet Kaur, Ankita Attri
How nutrition affects the cardiovascular risk 207
General dietary recommendations 209
38. CoQ10 and CVD Risk Reduction 2014 ................................................................. 211
   HK Chopra, Adarsh Kumar
   Potential clinical uses of CoQ10 in CVD risk reduction 211

39. CoQ10 in CHF and CAD: Potentials and Challenges Ahead ........................................ 214
   Adarsh Kumar, Harharpreet Kaur, Ankita Attri
   Role in congestive heart failure 214
   Role of CoQ10 in coronary artery disease 215

40. Edible Oils in Cardiovascular Disease Protection ......................................................... 218
   Shashank Joshi
   Fats and oils: basics 218
   Edible oil industry: global scenario 220
   Edible oil industry: Indian perspective 220
   Free radicals: health paradox 221
   Antioxidants: in human health 222
   Edible oils: antioxidants 222

41. Management of Obesity: By Optimizing Nutrition ....................................................... 224
   Sonia Arora, Vitull K Gupta, Meghna Gupta
   Weight control is a journey, not a destination 224
   What is obesity? 224
   Methods to calculate obesity 224
   Pathophysiology of obesity 225
   Causes of obesity epidemic in India 225
   How to manage obesity 225
   Drug therapy 228
   Weight loss surgery 228

SECTION 4: CARDIAC INVESTIGATION

42. Coronary Artery Disease and Biomarkers ................................................................. 233
   Satyavan Sharma, Satish Kumar, Suresh Kolekar
   Classes of cardiac biomarkers 233
   Role of cardiac biomarkers in CAD 234

43. Electrocardiogram: Pitfalls in Diagnosis and Artifacts ............................................... 237
   Amit Vora, Samhita Kulkarni
   Electrocardiogram: pitfalls in diagnosis 237
   Wrong lead placement 239
   Electrocardiogram artifacts 240

44. Echocardiography: Beginning, Present, and Future .................................................... 244
   Arka Chatterjee, Navin C Nanda
   1950–1990 244
   1990–Present 246
   Future 251

45. Stress Echocardiography and Coronary Artery Disease ............................................. 255
   Nitin Burkule
   Why do we need stress echo? 255
   Pathophysiology of ischemia and regional wall motion abnormality 255
46. Stress Myocardial Perfusion Imaging ................................................................. 263
   Johann Christopher, Raghu Krishnaswamy
   Choice of test modality 263
   Technical issues 266
   Exercise myocardial perfusion imaging for diagnosis 266
   Exercise myocardial perfusion imaging for prognosis 267
   Exercise myocardial perfusion imaging for choice of therapy 269

47. LV Diastolic Function Evaluation: What is Practical? ................................. 271
   SK Parashar
   Hemodynamic concepts of diastole 271
   What is diastolic dysfunction 272
   Echocardiographic techniques to evaluate diastolic dysfunction 272
   Hemodynamic determinants of Doppler parameters 275
   Types of diastolic dysfunction 275
   Basic rule of diastolic dysfunction 276
   Diagnosis of various grades of diastolic dysfunction 276
   Assessment of diastolic dysfunction in atrial fibrillation 278
   Clinical applications of diastolic dysfunction 279
   Suggested guidelines for subjective evaluation of filling, pressure (Nagueh et al., 1997) 280
   Diastolic stress echocardiography 280
   New diastolic indices 281

   George Thomas
   Cardiac changes in the elderly 283
   Characteristics of illness in elderly patients 284
   Problems of echocardiographic acquisition in elderly patients 284
   Common echocardiographic abnormalities in the elderly patients 284
   Echocardiographic diagnosis in the elderly patients 286

49. Myocardial Contrast Echocardiography: Usefulness and Pitfalls .................. 288
   Asrar Ahmed, Gurunathan Sothinathan, Jatinder Singh Pabla, Roxy Senior
   Pathophysiologic basis of MCE 288
   Role of MCE in clinical practice 288
   Pitfalls 292

50. Echocardiography and Post-MI Complications .............................................. 295
   P Krishnam Raju, K Raghu, Chandramukhi
   Complications of MI 295
   Cardiac rupture 296
   Mitral regurgitation 299
   Atrial infarction 302
   Diastolic dysfunction 302

51. Three-dimensional Echocardiography: Is it Superior to Two-dimensional ..... 305
   Echocardiography for Valvular Heart Disease .............................................
   Sameer Shrivastava, Vinay Kumar Sharma
   Acquisition of 3D data set: technical considerations 305
   Advantages of 3DE in evaluation of mitral valve disease 306
   Assessment of aortic valve 307
   Assessment of pulmonary valve 307
Assessment of tricuspid valve 308
Utility of 3D TEE during surgical and interventional procedures 308
Timing of surgery: the assessment of LV function 308

52. Strain and Strain Rate Imaging: Clinical Implications 2014 ................................................................. 310
Naveen Garg, KK Kapur

What is strain and strain rate? 311
Types of strains 311
Myocardial architecture 311
Rotational mechanics 312
Procedure and technique for performing strain imaging 313
Clinical applications of speckle tracking echocardiography 313

Myocardial diseases 314
Hypertension 314
Hypertrophic cardiomyopathy 314
Diabetes 314
Athlete’s heart 314
Coronary artery disease 315
Heart failure and dyssynchrony 315
Dilated cardiomyopathy 315
Stress cardiomyopathy 316
Pericardial diseases and restrictive cardiomyopathy 316
Valvular heart disease 316
Congenital heart disease 316
Heart transplant and rejection 316
Chemotherapy 316
Left atrial strains 316
RA strain 317
Limitations 317

53. Need of Cardiac Evaluation in Obesity ........................................................................................................ 322
CP Roy, Mitendra Singh Yadav

Cardiovascular pathophysiology/hemodynamics 322
Clinical assessment of adult obesity 324
Identifying the high-risk obese patient 326
Approaching obesity as a chronic disease 326

SECTION 5: ACUTE MYOCARDIAL INFARCTION

54. Management of Acute Myocardial Infarction in 2014 ..................................................................................... 331
Neeraj Parakh, VK Bahl

Prehospital management 331
Reperfusion therapy 332
Adjunct anticoagulant therapy with thrombolysis 334
Stem cell therapy 335
Indian scenario 336
Future directions 336

55. Thrombolysis in Acute Myocardial Infarction: Which Agent is the Right Choice? ........................................ 339
SS Iyengar

Thrombolytic agents 339
56. **Primary Angioplasty in 2014** .............................................................................................................................. 342
   Nagendra S Chouhan, Praveen Chandra
   Status of primary PCI in India 343
   Pharmacoinvasive approach to primary PCI 344
   Newer drugs in AMI armamentarium 344
   Newer devices in AMI armamentarium 346

57. **Thrombus Aspiration During Primary Percutaneous Coronary Angioplasty** .................................................. 351
   Dev B Pahlajani

58. **Cardiogenic Shock in Acute Myocardial Infarction** .......................................................................................... 354
   Ashwin B Mehta, Rahul Chhabria
   Definition of cardiogenic shock 354
   Incidence of cardiogenic shock 355
   Pathophysiology of cardiogenic shock 355
   Diagnosis 355
   Management of cardiogenic shock in AMI 355
   Treatment of cardiogenic shock 356

59. **Post-MI: Risk Stratification and Cardiac Rehabilitation** .................................................................................. 359
   Kushal Madan, JPS Sawhney
   Post-MI: risk stratification 359
   Post-MI: cardiac rehabilitation 362

60. **Revascularization in Acute Myocardial Infarction Patients 24 Hours after Thrombolysis** ............................ 367
   GR Kane, Piyush Goenka
   PAMI: best option out there! 367
   Rescue PCI 367
   Facilitated PCI 367
   Delayed routine and selective PCI 368
   PCI of an infarct artery versus non-infarct artery 368
   Stent in PCI 369
   Antiplatelet therapy to support delayed PCI after fibrinolysis 369
   Anticoagulant therapy to support delayed PCI after fibrinolysis 369
   Anticoagulant therapy to support primary PCI after fibrinolysis 369
   CABG in patients with STEMI 370
   Pharmacological therapy 370

61. **Thrombolytic Therapy in STEMI Interventions** ................................................................................................. 372
   Mehta S, Oliveros E, Reynbakh Q, Kostela J, Ossa MM, Zhang T,
   Botelho R, Rodriguez D, Botero M, Thomas J, Para D
   Guidelines for reperfusion therapy in acute myocardial infarction 372
   Benefits of choosing early reperfusion therapy 373
   Data supporting the use of thrombolytics in STEMI 373
   Other relevant trials 376
   Thrombolytic therapy for AMI managements in India 377
   Indigenous tenecteplase 378
   Is there room for thrombolytic therapy in the era of PPCI? 379
   Future perspectives 380
SECTION 6: CORONARY INTERVENTION

   Sudhir S Shetkar, Sandeep Singh, Sundeep Mishra
   Guidewires for chronic total occlusions 385
   Role of microcatheters in CTO PCI 386
   Strategies and wiring techniques 386
   Advance wiring techniques 387
   Advance wiring techniques for retrograde approach 389

63. Chronic Total Occlusion: Management Strategies 2014 ............................................................................. 392
   Pankaj Jariwala, K Sarat Chandra
   Definition, incidence, and presentation 392
   Success rates of chronic total occlusion intervention 394
   Challenges of chronic total occlusion lesions 394
   Imaging for chronic total occlusions 395
   Algorithm for crossing chronic total occlusions 395
   Guidewire selection and utilization 396
   Approach to the CTO 396
   Complications associated with CTO angioplasty 399
   Novel crossing and re-entry system in coronary chronic total occlusions 399
   Drug-eluting stent implantation for chronic total occlusions 400

64. Radial Angioplasty: Tips and Tricks ................................................................................................................... 402
   Sanjay Chugh, Yashasvi Chugh
   Overcoming the challenges 402

65. Guidelines for PCI 2014: Training for Percutaneous Coronary Intervention Appropriateness, Indications and Directions ....................................................................................................................................... 412
   Anil Dhall, Sanjat S Chiwane
   Competence and training standards 413
   Scores and risk stratification 414
   Decision making and patient information 414
   Timing of angiography and intervention in NSTEMI-USA group 415
   Timing of angiography and intervention in STEMI group 415
   Timing of angiography and intervention in chronic stable angina 416
   PCI in special groups 417
   Drug-eluting stents 418
   Drug-eluting balloons 418
   Biodegradable vascular scaffolds 419
   Adjunctive invasive diagnostic tools 419

66. Complex Coronary Angioplasty Procedure: Tips and Tricks ........................................................................... 423
   Viveka Kumar, Rajendra Kumar Agarwal
   Bifurcation lesions 424
   Fibrocalcific and undilatable lesions 425
   Chronic total occlusion 425
   ULMCA stenoses 425
   Thrombotic lesions 426
   Saphenous vein grafts 426
   Key points 426
67. Drug-eluting Stents: Differing Platforms and Outcome .........................................................428
   Shuvanan Ray, David Rozario
   Drug-eluting stents 428
   Drug reservoir technology 428
   Antiproliferative agents 428
   Limus analogues 429
   Drug-eluting stents platform 429
   Newer generation drug-eluting stents with durable polymer 430
   Biodegradable polymers 431
   Polymer-free drug-eluting stents 432
   Drug-eluting stents with durable polymers versus biodegradable polymers versus
   polymer-free drug-eluting stents 433
   Dual drug-eluting polymer-free stent versus durable polymer sirolimus-eluting
   stents versus durable polymer zotarolimus-eluting stent 433
   Platinum-chromium drug-eluting stents 433
   Bioresorbable vascular scaffolds 434

68. Role of Rotational Atherectomy in Percutaneous Coronary Interventions ..........................436
   Prashant T Upasani, Purshotam Lal
   Mechanism 436
   Equipment 436
   Procedure 437
   Lesion selection 437
   Indications 437
   Outcomes 438
   Clinical results 439
   Rationale for use 439

69. Can We Predict Stent Thrombosis and So Prevent It? .......................................................442
   Kajal Ganguly, Pradip Ghoshal, Santanu De, Arindam Basu
   What is stent thrombosis? 442
   Burden of stent thrombosis 442
   Prediction of stent thrombosis 443
   Prevention of stent thrombosis 444

70. Biovascular Scaffolds: New Dimension 2014 .................................................................446
   PC Rath, Sundar Chidambaram, B Dikshit
   Contemporary bioresorbable scaffolds and ongoing clinical trials 446

71. Indigenous Stents: Examining the Clinical Data on New Technologies ............................450
   Sreenivas Kumar Arramraju, Hariram Vuppaladadhiam
   Indigenous stents: historical perspective 450
   Indigenous bare metal stents 451
   Indigenous bare metal stents (with limited clinical data) 451
   Drug-eluting stents 451
   Peripheral 458
   Future perspectives 458

72. Hybrid Coronary Revascularization: An Integrated “Best of Both Worlds”
   Approach to Revascularization .........................................................................................461
   Harinder K Bali, Hiteshi KC Chauhan
   Introduction—the “hybridized wave” of the future? 461
   Evolution of HCR 462
Indications for HCR 463
Relative contraindications 463
Technical aspects of HCR 464
“Sequencing” HCR 464
Rationale for HCR 464
Factors against HCR 464
Current guidelines 464
HCR—Indian scenario 465

73. Management of Coronary Stent Restenosis: New Dimensions ................................................................. 468
Pravin K Goel, Jugal Sharma
Management of coronary stent restenosis: new dimensions 468
Definition, classification and mechanisms 468
Clinical presentation 469
Clinical approach and management 470

74. Saphenous Vein Grafts Intervention: Challenges 2014 ................................................................................. 474
Alok Mazumdar
Natural history of vein grafts 474
Pathophysiology of saphenous vein graft disease 474
Percutaneous treatment (PCI) of saphenous vein graft obstructions 475
Value of intravascular ultrasound in vein graft interventions 475
Strategies to prevent no-reflow in Saphenous vein graft interventions 475
The ACC/AHA indications for post-CABG-SVG Disease interventions 477
Practical approaches to SVG PCI 477

SECTION 7: PERIPHERAL VASCULAR INTERVENTION

75. Carotid Evaluation: How to Do, 2014 ................................................................................................................. 483
SS Mishra, BR Mishra, SN Routray, PK Pradhan, TK Mishra
Extracranial carotid atherosclerosis 483
Clinical examination 485
Imaging 485
Approach to imaging 486

76. Carotid Intervention: Current Status and Future Direction .............................................................................. 490
Rajneesh Kapoor, Peeyush Kumar Roy, Himanshu Dabral
Natural history of carotid artery disease 490
Benefits of carotid revascularization 491
Carotid artery stenting: clinical evidence 491
Carotid artery stenting: the procedural technique 492
Complications 494
Future prospective 494

77. Aortic Evaluation and Interventions: Status 2014 .......................................................................................... 496
NN Khanna, Suparna Rao
Evaluation 496
Coarctation of aorta 496
Aortic aneurysm 498
Thoracic aortic aneurysm 500
Abdominal aortic aneurysm 501
Aortic dissection 504
CSI Cardiology Update 2014

Takayasu arteritis 505
Atherosclerosis of aorta 510

78. Peripheral Vascular Evaluation and Intervention .......................................................................................... 513
CM Nagesh, BC Srinivas, Ashish Gupta, Babu Reddy
Epidemiology 513
Diagnosis and evaluation 513
Therapeutic strategies 516
Revascularization 516
Endovascular treatment 516
Acute limb ischemia 520

79. Chronic Lower Limb Ischemia: Management Strategies .............................................................................. 523
Amit Kumar, Atul Mathur
Epidemiology of PAD 523
Natural history of PAD 523
Clinical presentation 523
Imaging studies 524
Management of lower extremity PAD 524
Acute limb ischemia 525

80. Erectile Dysfunction and Coronary Artery Disease ....................................................................................... 529
Aditya Kapoor
Clinical assessment of erectile dysfunction 529
Coprevalence with cardiovascular disease 529
Association with severity of coronary artery disease 530
Is erectile dysfunction a greater predictor of cardiovascular disease in younger males? 530
Role of penile Doppler test 530
Does erectile dysfunction predict adverse cardiovascular events and cardiovascular disease mortality? 530
Is erectile dysfunction also present in those without manifest coronary artery disease 531
Pathophysiology and the role of endothelial dysfunction 531
Correlation with clinical mode of presentation of coronary artery disease 531
Erectile dysfunction often precedes coronary artery disease 532
Should erectile dysfunction patients be routinely screened for coronary artery disease? 532
Management of the erectile dysfunction patient with cardiovascular disease 532
Risk of sexual activity 533

SECTION 8: HEART FAILURE

81. Biomarkers in Heart Failure: Newer Horizon................................................................................................... 537
Amal Kumar Banerjee
Natriuretic peptides 538
Biomarkers of myocardial injury: cardiac troponin T or I 538
Extracellular matrix markers 539
Aldosterone 539
Markers of inflammation 539
Adrenomedullin 539
Copeptin 539
Neutrophil gelatinase-associated lipocalin 539
Kidney injury molecule-1 539
Quiescin Q6 539
High-sensitivity ST2 539
Galectin-3 540
Multimarker approaches 540

82. Echo and Diastolic Heart Failure ................................................................. 542
Satish C Govind, Harsha Basappa
Pathophysiology 542
Causes 542
Diagnosis 543
Echocardiography 543

83. BNP Evaluation Guidelines in CHF .................................................................... 546
Jabir A, Jo Joseph, Rony Mathew Kadavil
Natriuretic peptides 546
BNP metabolism 546
NT-proBNP versus BNP 547
Causes of NP elevation 547
NP levels lower than expected 547
Clinical utility of BNP 547
BNP in differentiating dyspnea of cardiac origin 547
BNP consensus algorithm and optimal NT-proBNP cutoff points 547
Natriuretic peptides in the prognosis of heart failure 547
Monitoring therapy and optimizing outcomes 547
Caveats in the use of NPs 548

84. Anemia in Chronic Heart Failure ........................................................................ 551
Vidyut Jain, Avani Jain
Etiology of anemia in chronic heart failure 551
Pathophysiology of anemia in chronic heart failure 552
Treatment of anemia in chronic heart failure 553

85. When to Revascularize in Heart Failure? ........................................................... 557
G Sengottuvelu, R Ravindran, Dattagupta Aditi
Definition of ischemic LV dysfunction 557
Mechanism of ischemic LV dysfunction 557
Assessment of viability 558
Evidence for revascularization in heart failure 559

86. Acute Decompensated Heart Failure .................................................................. 561
Mohit D Gupta, MP Girish, Jyoti Prakash Lal Karn
Diagnosis 561
Treatment strategies of ADHF 562
Pharmacologic agents in development for ADHF 566

87. Managing Comorbidities in Heart Failure ......................................................... 569
Nakul Sinha
Diabetes 570
Hypertension 570
Anemia 570
Fatigue/generalized weakness 571

88. CHF and CKD—Double Jeopardy: How to Manage? ........................................... 573
UC Samal, Anand Santosh
Preamble 573
CSI Cardiology Update 2014

Management 573
Pathophysiology 574

89. Heart Failure Management in Women: Is it Different? .......................................................... 577
Chetan P Shah
Epidemiology of heart failure 577
Etiology 578
Prognosis 578
Pharmacologic interventions in management of women with heart failure 578
Nonpharmacologic interventions 580

90. Left Ventricular Assist Devices: New Frontiers 2014 .......................................................... 581
Vishal Rastogi, Bhumika S Anand
Surgically implanted VAD 581
Pre-procedural planning 582
Percutaneous left ventricular assist devices 583

SECTION 9: HYPERTENSION

91. Approach to a Newly Diagnosed Hypertensive ................................................................. 589
Dhiman Kahali, Paramita Banerjee
Definition 589
Diagnosis and initial evaluation 590
Evaluation of target organ damage 590
Secondary hypertension 590
General approach to patient 591
Specific strategies and approach for patient in different age groups 591
Approach to hypertension treatment 593

92. Ambulatory BP Monitoring: Is It Really Essential? ....................................................... 595
George Koshy A, Sajan Ahmad Z
Ambulatory BP monitoring—why? 595
Ambulatory BP monitoring—how is it done? 595
Ambulatory BP monitoring—major roles 596
Ambulatory BP monitoring—additional roles 597
Ambulatory BP monitoring targets in hypertension management 598
Ambulatory BP monitoring—logistic issues 598
Ambulatory BP monitoring—what the guidelines say 599

93. Cardiovascular Risk in Hypertension: How to Manage It? ........................................... 602
A Banerji, S Sengupta
Definitions 602
Epidemiology of cardiovascular disease and hypertension 602
Indian epidemiological perspective 603
Markers of increased cardiovascular risk in hypertension 603
Management of hypertension 603

94. Role of Echocardiography in Hypertension ................................................................. 607
Hardeep Kaur Grewal, Manish Bansal, Ravi R Kasliwal
Pathophysiology of hypertension 607
Role of echocardiography in hypertension 607
95. Nonpharmacological Management of Hypertension 2014 .................................................................617
Pramod Joshi, Ashish Jai Kishan, Suman Bhandari
Recommended lifestyle modifications 617

96. Resistant Hypertension: Clinical Evaluation and Management .................................................................622
Mohsin Wali, Sanjeev Sharma, C Venkata S Ram
Pseudoresistance to therapy 623
Pathobiology of resistant hypertension 623
Renal artery stenosis 624
Chronic kidney disease 624
Primary aldosteronism 624
Pheochromocytoma 624
Other endocrine disorders 624
Obstructive sleep apnea syndrome 625
Non-drug therapy 625
Correction of secondary causes 625
Pharmacological options and principles to treat resistant hypertension 626
Maximize adherence 626
Antihypertensive drug dosing 626
Adjusting the diuretic therapy 626
RAAS blockers 626
Calcium channel blockers 626
Other antihypertensive drugs 627
Mechanical device-based therapy 627
Unanswered questions 627

97. Indian Practical Guidelines for Management of Hypertension .................................................................629
Rakendra Singh, Abhishek Goyal, Gurpreet S Wander
The third Indian guidelines on hypertension (IGH)-III 629
Epidemiology 629
Definition and classification 629
Measurement of blood pressure 630
Management of hypertension 631
Secondary hypertension 633
Hypertension in special situations 633
What is new in third Indian hypertension guidelines 633

98. Choosing the Right Drug for Your Hypertensive Patient: A Look at Comorbidities .................................................................635
Narender O Bansal, Sandesh Prabhu
Chronic kidney disease 635
Elderly hypertensives 635
People with coronary artery disease 636
People with congestive heart failure 636
People with diabetes 637
People with high cholesterol 637
People with respiratory disease 637
People with gout and hyperuricemia 637
Liver diseases 638
Hypertension in pregnancy 638
Antihypertensive in breastfeeding 638
Obstructive sleep apnea syndrome 638
Obesity 639
Metabolic syndrome 639

99. Renal Denervation: Present Status and Future Direction.................................................................640
Arup Dasbiswas, Debasis Dasbiswas
Resistant hypertension 641
Renal denervation quick facts 641

100. Recent Advances in Hypertension Management for Cardiovascular Disease Prevention ..........................................................646
Rajeev Gupta
Hypertension as cardiovascular risk factor 647
Primordial prevention and lifestyle changes 647
Pharmacotherapy and interventions 649
Health systems approach 651

101. Hypertension Paradoxes.................................................................................................................654
Jagdish Hiremath, Kaushik Sheth
Effectiveness of therapy 654
Step care approach 654
Combination therapy 654

102. Hypertension Management Strategy in Renal Artery Stenosis ..........................................................656
TK Mishra
Scenario 656
Renovascular syndromes with RAS 656
Functional classification of atherosclerotic RAS 656
Pathophysiology of renovascular hypertension 656
Hypertension in RAS 657
Medical therapy of renovascular hypertension 657
RAS and refractory hypertension 658
Revascularization 658
Endovascular renal angioplasty and stenting 658
Lessons learnt 659
Cause of no drastic benefit of revascularization in ARAS 660
Surgical modality 660

103. Central Aortic Blood Pressure as a Prognostic Marker in Hypertension .................................................661
C Venkata S Ram
Central aortic pressure and arterial stiffness in cardiovascular disease 661
Central aortic pressure and arterial stiffness as predictors of cardiovascular risk in outcome studies 662
Assessment of CAP and arterial stiffness 662
Therapeutic effect of antihypertensive drugs based on central and peripheral BP levels 663

SECTION 10: VALVULAR HEART DISEASE

104. TAVR Present Status and Challenges Ahead ......................................................................................669
Vijay Kumar, Ashok Seth
Current Status of TAVR 669
TAVR technology today and the challenges ahead 670
Prosthesis durability 671
Valve in valve TAVR 672
Imaging in TAVR 672
Vascular access site issues 674
Other ongoing issues with TAVR and the Challenges 675
Stroke 676

105. Percutaneous Mitral Valvuloplasty: Tips and Tricks................................................................. 681
   KC Goswami, Sunil Kr Verma
   Clinical profile of the patient 681
   Echocardiography 681
   Transseptal catheterization 682
   Preparation of balloon 683
   Crossing the mitral valve 683
   Safe and Effective balloon dilation 684
   Avoiding complications specially Mitral Regurgitation 684

106. Rheumatic Heart Disease: Epidemiology and Management................................................ 687
   Arati Dave Lalchandani, Manoj Godara, Navin Mathiyalagan
   Epidemiological factors 687
   Epidemiology 687
   Management 688

107. Echocardiography in Rheumatic Heart Disease........................................................................... 691
   IB Vijayalakshmi
   Background 691
   Transthoracic echocardiography 691
   Echocardiography versus clinical examination 691
   Accurate diagnosis is eluding clinicians 692
   Echocardiography features of carditis 692
   Is echocardiography superior in the diagnosis of carditis? 693
   Integrative approach to assessment of severity of mitral regurgitation 693

108. Percutaneous Valve Repair/Replacement: Status 2014 ..............................................................697
   Sunil Vanzara, Ramakanta Panda
   Transcatheter aortic valve replacement 697
   Indications 697
   Technique 698
   Technical considerations 698
   Results 699
   Partner trial 700
   Complications 701
   Future 702
   Transcatheter mitral valve repair 704
   Valve-in-valve for failing bioprostheses 704

109. Prosthetic Valve Thrombosis: Management Strategies ..............................................................706
   G Karthikeyan
   Clinical presentation 706
   Diagnosis 706
   Treatment 707
   Key points 709
110. Echo Navigation: A Glimpse into the Future ................................................................. 711
   Ashok K Omar, Nishant Kumar
   Newer catheter-based approaches 711

111. Complex Issues in Aortic Valve Diseases ................................................................. 716
   Hardeep Kaur Grewal, Manish Bansal, Ravi R Kasliwal
   Aortic stenosis 716
   Aortic regurgitation 721
   Bicuspid aortic valve in absence of severe AS or AR 721

SECTION 11: CARDIOMYOPATHY

112. Management of Dilated Cardiomyopathy ............................................................... 727
   Ajay Behl, KK Talwar
   Evaluation 727
   Treatment 728

113. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Current Status ................................................................. 730
   I Sathyamurthy, K. Jayanthi
   Hypertrophic cardiomyopathy 730
   Treatment options 730
   Procedure of alcohol septal ablation 730
   Mechanism of treatment efficacy 731
   Adverse events 731
   Case selection for alcohol septal ablation 731
   Harm 731
   Trials of alcohol septal ablation 731
   Future novelties 732

114. Genetic Evaluation in Hypertrophic Cardiomyopathy ............................................. 733
   Ajay Bahl
   What is the genetics of hypertrophic cardiomyopathy? 733
   What are the problems in genotyping hypertrophic cardiomyopathy? 733
   What is the significance of identified sequence variations? 734
   What is the role of genotyping in family screening? 734
   What are the clinical situations where screening is useful? 734
   Does genotyping help in risk stratification? 734
   What are the limitations of screening? 734

115. Restrictive Cardiomyopathy: Management Strategies .......................................... 736
   Harsh Wardhan, Ankur Agarwal
   Restrictive cardiomyopathy 736
   Specific causes and their treatment 738

116. Peripartum Cardiomyopathy ...................................................................................... 740
   SB Gupta
   Definition 740
   Epidemiology 740
   Nomenclature 740
   Etiopathogenesis 741
   Clinical features 741
   Differential diagnosis 741
Diagnosis  741
Risk factors  742
Management  742
Prognosis  742

117. Stress Cardiomyopathy ........................................................................................................744
Roopa Salwan
Prevalence  745
Concepts about pathophysiology  745
Multivessel epicardial coronary artery spasm  745
Coronary microvascular impairment  745
Catecholamine cardiotoxicity  745
Patient demographics and presenting signs and symptoms  746
Echocardiographic findings  746
Echocardiography  747
Cardiac magnetic resonance imaging  747
Cardiac catheterization and angiographic findings  748
Systolic and diastolic dysfunction in stress cardiomyopathy  748
Management  750
Recurrence rate and prognosis  750

SECTION 12: DYSLIPIDEMIA AND CARDIOMETABOLISM

118. High Sensitivity C-reactive Protein: The Most Powerful Predictor of Occult Cardiovascular Disease in Patients of Metabolic Syndrome: A Hospital-based Study. .................................................................................................................. 755
HK Chopra, Pranjali Gupta, Krishna CK, KK Aggarwal, RS Sambi
Materials and methods  755
Results  756
Discussion  759

119. Heart Disease and Exercise in Cold Weather ........................................................................762
Peeyush Jain
Cold weather and the heart  762
Mechanism of angina in cold weather  762
Local exposure may also be deleterious  762
Mouth breathing precipitates coronary spasm  763
Type of exercise influences the outcome  763
Special situations  763
Safety rules for exercise in cold weather  763

120. Exercise and CVD Protection in Metabolic Syndrome ................................................................765
Pankaj Manoria, PC Manoria
Exercise and obesity  765
Exercise and insulin resistance  765
Exercise and glucose intolerance  766
Exercise and hypertension  766
Exercise and dyslipidemia  766

121. Obesity, CAD and Heart Failure: A Triple Jeopardy ................................................................770
SN Routray, Debasis Das, TK Mishra, SS Mishra
With a very heavy heart: obesity and cardiovascular disease  770
Adipose tissue is an endocrine organ  770
Myocardial injury 770
Role of pericardial fat 771
Hemodynamic repercussion of obesity 771
Vascular injury 771
Obesity and coronary artery disease 771
Obesity myocardial infarction paradox 771
Obesity and heart failure 772
Effects on ventricular function 772
Cardiomyopathy of obesity (adipositas cordis) 772
The “obesity paradox” and heart failure: the story continues 772
Sudden cardiac death 772
Impact of obesity on total and cardiovascular mortality—fact or fiction 772
Fitness versus fatness 773
Management 773

122. Review of First Approved Dual PPAR α/γ Agonist, Saroglitazar: A Cardiologist’s Perspective .......................................................... 774
PC Manoria, HK Chopra, Tiny Nair
Cardiovascular diseases 774
Atherogenic dyslipidemia in type 2 diabetes 774
Modulation of PPARs and CV risk reduction 775
Saroglitazar—the first approved glitazar 777

SECTION 13: DIABETES AND HEART

123. CAD Preventive Strategies in Diabetes Mellitus .......................................................... 783
Ajay Kumar Sinha, Vikas Singh, Pramod Kumar, Anand Gopal, Sanjeev Kumar
Optimal glycemic control in cardiovascular risk reduction 783
Optimal blood pressure control 784
Cholesterol management 784
Smoking cessation 785
Lifestyle modification 785
Drugs—aspirin 785

124. Management of Coronary Artery Disease in Diabetes Mellitus—Is It Different? ......................... 787
Asha Moorthy, Jain T Kallarakkal
Relationship between glycemic control and cardiovascular disease 787
Medical management in acute coronary syndromes 787

125. CAD and CKD: A Double Jeopardy Management Strategies .................................................. 790
ST Yavagal
Management of CAD with CKD 790
Evaluation for CAD 791
Treatment 791
Prognosis 792

SECTION 14: PREGNANCY AND HEART

126: Hypertension in Pregnancy: Management Strategies .................................................................. 795
Vitull K Gupta, Sonia Arora, Meghna Gupta
Definition of hypertension 795
Classification of hypertensive disorders of pregnancy 795
Management strategies 796
127. Management of Valvular Heart Disease in Pregnancy

Rajiv Bajaj

- Physiology
- Antenatal care
- Delivery
- Mitral stenosis
- Mitral regurgitation
- Mitral regurgitation with mitral stenosis
- Aortic stenosis
- Aortic regurgitation
- Right-sided valvular disease
- Multivalvular disease
- Endocarditis
- Congestive heart failure
- Arrhythmias
- Surgical correction during pregnancy
- Prosthetic valve management

Key points

128. Pregnancy and Pulmonary Embolism: How to Manage?

M Somasundaram, K Meenakshi

- Predisposing factors
- Diagnosis
- Differential diagnosis
- Treatment
- Prophylaxis

SECTION 15: TROPICAL CARDIOLOGY

129. Management of Takayasu’s Arteritis

Sanjay Tyagi, Amit Mittal

- Diagnosis and assessment of disease activity
- Treatment
- Surgery
- New perspectives and special considerations

130. Uremic Cardiomyopathy: Is it an Entity?

AK Kar, Ayan Kar

- Treatment
- Newer treatments

SECTION 16: CARDIOPULMONARY DISEASES

131. Pulmonary Embolism Management Strategies 2014

K Venugopal, Anjith Vupputuri

- Incidence
- Risk factors
- Pathophysiology
- Diagnosis
- Clinical presentation
- Management
- Role of IVC filters in pulmonary embolism
- Newer oral anticoagulants (NOACS)
132. Tenecteplase and Acute Pulmonary Embolism: A Revolution

Lekha Adik Pathak

Thrombolytic therapy for acute pulmonary embolism 830
Tenecteplase: a stronger contestant in the race of thrombolytics 831
Evidence base for use of tenecteplase in acute pulmonary embolism 831

133. Imaging in Pulmonary Hypertension

S Shanmugasundaram, Madhan Shanmugasundaram, B Vinodhkumar

Why do we need imaging in suspected pulmonary hypertension patients? 834
Who needs pulmonary hypertension imaging tests? 835
What are the imaging modalities that are useful in evaluation of pulmonary hypertension? 835
Do we need to order all the tests in each of pulmonary hypertension suspects? 835
How does ECG help in diagnosis of pulmonary hypertension? 835
What are the findings in chest X-ray that suggest pulmonary hypertension? 835
How does echocardiography assist the clinician in obtaining diagnostic and prognostic information? 837
Invasive hemodynamics and pulmonary angiography 848

134. Treating Pulmonary Arterial Hypertension in 2014

Abhinit Gupta, S Ramakrishnan

Evolving classification of PAH: evolution of treatment algorithms 852
Targeted treatment of PAH 855
Prostanoids 855
Endothelin receptor antagonists 856
Phosphodiesterase-5 inhibitors 857
Soluble guanylate cyclase stimulators 857
Interventional therapies 858

135. Pulmonary Arterial Hypertension: Current Treatment’s Success and Failure

Saroj Mondal, Madhumanti Panja, Priyam Mukherjee, Manotosh Panja

Calcium channel blockers 862
Endothelin receptor antagonists 862
Prostacyclin analogs 863
Phosphodiesterase-5 inhibitors 863
Combination treatments 863
Pulmonary artery denervation to treat PAH 864
Palliative and supportive treatments for residual dyspnea in progressive PAH 864
Future prospects 865

136. Chronic Thromboembolic Pulmonary Hypertension

BKS Sastry

Pathophysiology 870
Clinical presentation 870
Diagnostic work-up 871
Treatment 871
Pulmonary thromboendarterectomy—surgery for chronic thromboembolic pulmonary hypertension 872
Surgical results 872
Postoperative residual pulmonary hypertension 872
Postoperative follow-up 872
Pulmonary arterial hypertension-specific therapies 872
Balloon angioplasty 873
Lung transplantation 873
Rony Mathew, Karthik Tummala, Jo Joseph
Key principles in resuscitation: strengthening the links in the chain of survival 874
Chest compression only CPR in witnessed out-of-hospital cardiac arrest 875
Is cardiopulmonary resuscitation first or defibrillation first? 875
Devices in cardiopulmonary resuscitation 876
When should cardiopulmonary resuscitation be stopped? 877
Should we allow family member to witness cardiopulmonary resuscitation? 878
Should hypothermia be a part of the postcardiac arrest care? 878

138. Failing RV in PAH—How to Manage?
Vinay Jaiswal, Jivtesh Pahwa, Prafulla Kerkar
Normal RV 879
Right ventricle in pulmonary arterial hypertension 879
Ventricular interdependence 880
RV failure 880
Echocardiography using pulse Doppler to perform MPI 883
Prognostic indicators in PAH 884
Specific drugs 885

139. Anticoagulants in Venous Thromboembolism
VS Narain, Gaurav Kumar Chaudhary
Initial anticoagulation therapy in VTE 890
Prevention of Venous Thromboembolism 892
Future needs 892

SECTION 17: PACING AND ELECTROPHYSIOLOGY

140. Epidemiology of Sudden Cardiac Death—India versus West
Pushpraj Patel, B Hygriv Rao
Epidemiological assessment of SCD 897
Incidence and prevalence of SCD 898
SCD following st elevation myocardial infarction 898
Inherited arrhythmia syndromes leading to SCD 899

141. Markers of Sudden Cardiac Death
Praveen Jain, Ram Babu, Tanul Jain
Markers of sudden cardiac death 902
Electrocardiographic measures 903
Autonomic nervous system 905
Repolarization abnormalities 906
Current guidelines in management and prevention of sudden cardiac death 907
Challenges facing current risk stratification strategies 908

142. Sudden Cardiac Death: How to Prevent?
Ulhas Pandurangi
Definition 909
Epidemiology 909
Risk stratification 909
Implantable cardioverter defibrillator 910
Pharmacotherapy 911
143. Sudden Cardiac Death in Athletes: Is it Different? ............................................................................................. 912
BP Singh, Ravi Vishnu Prasad, Nishant Tripathy, Nirav Kumar, Pawn Kumar, Shamboo Kumar
Causes of sudden cardiac death in athletes 912
Evaluation of athletes 914
Structural changes of heart as a result of intense training 915
Black athletes 915
Management strategies for prevention of sudden cardiac death in athletes 916

144. Diagnosis and Management of Syncope ................................................................................................. 920
Rabin Chakraborty
Neurogenic control of the heart and its effects on blood pressure 920
Diagnostic evaluation of neurocardiogenic syncope 921
Syncope secondary to structural cardiac or cardiovascular disease 924
Unexplained syncope in patients with high risk of sudden cardiac death 926

145. Atrial Fibrillation: Current Management Strategies ...................................................................................... 928
Dayasagar Rao, Nishad Chitnis
Classification 928
Management strategies 928

146. Atrial Fibrillation with Thromboembolic Stroke: Management Strategies ......................................................... 935
Geetha Subramanian
Types of atrial fibrillation 935
Primary prevention of stroke in atrial fibrillation 936
Risk stratification 936
Assessment of bleeding risk 937
Antithrombotic therapy 938
Antiplatelet agents 938
Anticoagulants 938
Novel oral anticoagulants 938
Features of stroke in atrial fibrillation 939
Rate and rhythm control 939
Defibrillation 940
Upstream therapy 940
Nonpharmacologic stroke prevention 940
Catheter ablation for rhythm control in atrial fibrillation 941
Secondary prevention of stroke 941
Key points 941

147. Tilt-Table Testing: Clinical Implications and Challenges Ahead ................................................................. 943
K Meenakshi
Indications 943
Precautions 944
Clinical significance and implications 944

148. Ventricular Tachycardia: Recent Advances ...................................................................................................... 946
Aparna Jaswal, Malay Shukla
Prognostic significance 946
Advances in the management of ventricular tachycardia 946
Surgery for ventricular arrhythmias 950
149. Long and Short QT Syndrome: How to Manage? ................................................................. 953
   Subhendu Mohanty, Sameena Khalil, M Khalilullah
   Long QT syndrome 953
   Short QT syndrome 957

150. Automated Blood Pressure: A Review .............................................................................. 961
   C Varun, Rakesh Yadav
   Rise of chronic diseases and cardiovascular mortality in India 961
   Burden of hypertension in India 961
   Oscillometric technique 962
   How to take BP with an automated device? 963
   Use in patients with atrial fibrillation 963
   Validation of instruments 963
   Use of hand and wrist devices 963
   Detection of atrial fibrillation with automated devices 963

151. Which Patients may Benefit More by Giving Antihypertensive Drugs at Night? .................. 965
   RK Saran, Gaurav Kr Chaudhary
   Significance of nocturnal blood pressure 965
   Normal circadian pattern of blood pressure 965
   Gradation of nocturnal blood pressure dipping 965
   Dipping status in diabetic, CKD and resistant hypertensive patients 966
   ESH criteria for nocturnal hypertension 966

152. Approach to Broad QRS Tachycardia ................................................................................ 969
   SK Dwivedi
   Differential diagnosis 969
   Clinical approach to wide complex tachycardia 969
   Electrocardiogram approach to wide complex tachycardia 970
   ECG algorithms for wide complex tachycardia 971
   Limitations of morphological criteria 972

153. Ventricular Tachycardia in a Structurally Normal Heart .................................................. 974
   Ajay Naik
   Clinical presentation and evaluation 974
   Non-life-threatening ventricular arrhythmias, typically monomorphic 974
   Life-threatening ventricular arrhythmias (typically polymorphic) 978

154. Cholinergic Tachyarrhythmia: New Dimension 2014 ......................................................... 983
   PB Jayagopal, Jain T Kallarakkal, Anoop Gopinath
   Vagal atrial fibrillation 983
   Other forms of cholinergic arrhythmia 984

155. Tips and Tricks of CRT Implantation .................................................................................. 985
   Neeraj Pandit
   General guidelines for CRT implantation procedure 985
   Cannulation of coronary sinus 986
   Location of coronary sinus os and advancement of sheath with contrast injection 986
   Anatomy of coronary sinus 986

156. Syncope and Cardiovascular Link ..................................................................................... 989
   KK Sethi, Kabir Sethi, SK Chutani
   Synonyms of vasovagal syncope 989
   Epidemiology of syncope 989
SECTION 18: CEREBROVASCULAR DISORDERS

157. Stroke in Cardiac Patients: Preventive Strategies
Sandesh Prabhu, Anil Kumar
Natural history of stroke 1003
Atherosclerosis and stroke prevention 1004
Cardioembolic strokes: atrial fibrillation 1004
Left ventricular thrombi as a source of cardioembolic stroke 1005
Atherosclerotic disease of the ascending aorta and aortic arch and risk for ischemic stroke 1005
Paradoxical embolism 1005
Hypertension and stroke 1005
Prevention of intracerebral hemorrhage 1005
Carotid endarterectomy and carotid artery stenting 1005
Lifestyle and stroke prevention 1006

158. Acute Ischemic Stroke
SV Patted, Prabhu Halkatti, Ravi Solbannavar
Epidemiology 1008
Pathophysiology 1008
Etiology of ischemic stroke 1009
Classification of acute ischemic stroke 1009
Diagnosis of ischemic stroke 1010
Treatment 1011

SECTION 19: CONGENITAL HEART DISEASE

159. A Clinical Approach to Common Acyanotic Congenital Heart Diseases
Neeraj Awasthy, Savitri Shrivastava
Classification of ACHD 1017
Pathophysiology of ACHD 1017
How to suspect ACHD 1019
Auscultation in individual ACHD 1021
Chest X-ray 1023
Electrocardiogram 1024

160. How to Deliver the Best Care for Patients with Congenital Heart Disease in India
Anita Saxena
Burden of the disease in India 1028
Current status of pediatric cardiac care in India 1028
Factors responsible for current state 1029
Strategies for delivering the best to the least affording populations of India 1030
161. Interventions in Common Congenital Shunt Lesions ..................................................................................................1033
S Mani Ram Krishna, R Krishna Kumar
Atrial septal defects 1033
Patent ductus arteriosus 1037
Ventricular septal defects 1040

162. Atrial Septal Defect in Adults: Management Approach New Dimension.........................................................1045
Smita Mishra
Principles of management of atrial septal defects 1045
Medical management 1045
Catheter intervention in atrial septal defect 1047
Surgery 1050
Outcome of atrial septal defect closure 1050

163. Eisenmenger Syndrome—An Update....................................................................................................................1054
Snehal Kulkarni, Prashant Bobhate
Definition 1054
Epidemiology 1054
Classification 1054
Pathophysiology 1054
Natural history 1055
Clinical features 1055
Investigations 1056
Management strategy 1056
Future trends 1058

SECTION 20: CARDIAC SURGERY

164. Cardiac Surgery in India: Present Status and Future Challenges...............................................................................1063
N Trehan, U Dhir
Minimally invasive surgeries 1063
Transcatheter valves 1063
Indications 1064
Heart failure surgery 1064
Robotic surgery 1064
Stem cell and gene therapy 1064

165. Robot-assisted Cardiac Surgery ................................................................................................................................1066
Yugal K Mishra, Syed Asrar Ahmed Qadri
Robot-assisted coronary artery bypass graft 1067
Robotic internal mammary harvest 1067

166. Aortic Valve Surgery in 2014: Challenges Ahead ...................................................................................................1072
OP Yadava, A Kundu
Minimally invasive aortic valve surgery 1072
Transcatheter aortic valve implantation 1072
Sutureless valves 1074
New heart valve designs 1074
Imaging 1076
167. A New Era in Heart Transplantation with Donation after Circulatory Death
Manoj Agny
- Warm preservation 1079
- Donation after circulatory death procedure 1079
- Clinical trials 1080
- Ethical angle 1080
- Comment 1081

168. Total Arterial Minimally Invasive CABG in Multivessel Disease—The Nambiar Technique
Pradeep Nambiar
- Methods 1082
- Results 1084
- Comment 1085

169. Management of Aortic Dissection and Aneurysms: Recent Advances 2014
Devi Prasad Shetty, Binoy Chattuparambil
- Acute aortic syndrome 1087
- Management of aortic aneurysm 1090

SECTION 21: STEM CELL THERAPY
170. Potential of Stem Cell Banking in India
Vinod K Shah, Kavita K Shalia
- Stem cell bank 1095
- Cord blood cells and cord blood bank 1096
- Stem cell banking in India 1096
- Umbilical cord blood transplantation in India 1096
- Regulatory environment in India and other countries 1097
- What is the global and Indian scenario of stem cell therapy? 1097

SECTION 22: NEW CARDIAC IMAGING MODALITIES
171. Cardiac MRI: Promise, Hope, and Hype
Mona Bhatia
- Technical aspects of cardiac MRI 1101
- Image acquisition 1101
- Imaging planes 1102
- Indications and applications 1102
- Future developments 1106

172. CT Coronary Angiography: Friend or Foe to the Cardiologists?
Rochita Venkataramanan
- CT angiography is safe, comfortable and accurate 1108
- Prognostic value of CT angiography for major adverse cardiac events: scoring over the clinical risk model 1108
- CT angiography value in the emergency room 1109
- CT angiography usefulness for percutaneous coronary intervention and thrombolysis 1109
- CT angiography and CT myocardial perfusion help find the culprit artery 1110
- Plaque regression assessment by CT angiography 1110
- CTA and catheter angiogram disagreement on percentage stenosis 1110
- Appropriateness criteria for CTA 1111
173. Clinical Value of SPECT and PET in CAD ................................................................. 1113
   GN Mahapatra
   Clinical application of spect myocardial perfusion imaging  1114
   Clinical applications of positron emission tomography myocardial perfusion imaging  1115
   Emerging concepts in clinical applications  1122

174. The MOGE(S) Classification of Cardiomyopathy: Is it Relevant in India and Other Low and Middle-income Countries? ................................................................. 1126
   Eloisa Arbustini, Jagat Narula

SECTION 23: ECMO

175. ECMO in ICU ........................................................................................................... 1135
   Yatin Mehta
   Background  1135
   Aims of ECMO  1135
   ECMO terminology  1135
   Decision to institute ECMO  1135
   Contraindication of ECMO  1135
   Types of ECMO  1136
   VV ECMO  1137
   VA ECMO  1138
   Central versus peripheral ECMO  1139
   Uses of ECMO  1140
   ECMO for cardiac surgery  1140
   ECMO in cardiogenic shock  1140
   ECMO in heart failure  1140
   ECMO and sepsis  1141
   Noncardiac indications for ECMO  1143
   Acute respiratory distress syndrome  1143
   Clinical trials  1143
   ECMO and CRRT  1143
   ECMO and organ preservation  1144
   ECMO and lung transplantation  1145
   Meconium aspiration and ECMO  1147
   Novoseven use in a noncardiac pediatric ECMO patient with uncontrolled bleeding  1147
   Circuit management  1147
   Past and future of ECMO: the cardiohelp  1149
   ILA activeâ€”(Novalung, Germany) for CO2 removal during ECMO  1150
   Complications  1150

176. Echocardiography in Extracorporeal Membrane Oxygenation ................................................................. 1152
   Poonam Malhotra
   Types of ECMO  1152
   Indications of VV ECMO and VA ECMO  1152
   Cardiac indications of ECMO  1153
   Venoarterial ECMO versus ventricular assist device  1154
   Venoarterial ECMO for cardiorespiratory failure  1155
   ECMO as bridge to transplant  1155
   Venoarterial ECMO contraindications  1155
   Quantification of differential ECMO return flow through an axillary artery anastomosis graft with spectral Doppler echocardiography  1155
Echocardiography has a pivotal role throughout the care of patient's support on ECMO 1156
Echocardiography before ECMO commencement (selection of patients) 1156
Echocardiography during ECMO initiation and cannulation 1158
Echocardiography and monitoring ECMO response 1163
Echocardiography in detection of ECMO complications 1166
Echocardiography during patient's recovery and weaning of support 1169
Pitfalls of echo in ECMO 1171
Echo is fundamental during ECMO in following ways 1171

SECTION 24: MISCELLANEOUS

177. Medicolegal and Ethical Issues in Cardiology Practice: How to Defend a Complaint and/or a Judgment against a Doctor for Alleged Professional Misconduct? 1175
   KK Aggarwal
   Defenses in professional misconduct 1175

   Sada Nand Dwivedi
   Background 1181
   Scales of measurements 1181
   Major steps under research methodology 1181
   Data collection: bias, confounding and effect modification 1183

179. How to Be a Good Cardiologist? 1186
   RP Sapru
   Professional attributes 1186
   Academic attributes 1188
   Personal attributes 1188
   Social attributes 1188

180. Hemodynamic Features of Constrictive Physiology 1190
   V Jacob Jose
   Classical or traditional hemodynamic features of constrictive physiology 1190

181. Corus CAD Test: A Gene Expression Test to Help Exclude the Diagnosis of Obstructive Coronary Artery Disease 1195
   Mark Monane
   Test description 1196
   Clinical studies 1196

182. Recent Advances in the Pathophysiology of Cardiac Muscle 1201
   RK Kotokey, Patil Vijay Kumar, Nayanjyoti Bez, Atul Pandey, Sayyed Imran, Luhamdao Bathari

183. Pharmacogenetics and Pharmacogenomics: Future of Cardiovascular Therapeutics 1204
   Ranjith MP, Divya Raj R, Dourado PMM
   Statins: variability in efficacy and risk of myopathy 1204
   Antiplatelet drug resistance 1205
   Oral anticoagulants 1206
   Beta-blockers 1206
   Angiotensin-converting enzyme inhibitors 1206
   Future perspectives 1207
184. What the Adult Cardiologist Should Know about Cyanotic Congenital Heart Disease?

P Syamasundar Rao

Tetralogy of Fallot 1209
Transposition of the great arteries 1210
Truncus arteriosus 1211
Total anomalous pulmonary venous connection 1211
Tricuspid atresia and other single ventricle lesions 1212
Surgical correction in adulthood 1213

Index 1217